180400.KQ Cancer Rop Co. Ltd.
- Market cap
- KRW 179B
- P/E
- -
- P/B
- 2.17x
- ROE
- -29.3%
- Dividend yield
- -
- Fundamental score
- 0.9/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 180400.KQ undervalued?
Graham numberThe Graham number of Cancer Rop Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cancer Rop Co. Ltd. fundamental analysis
4 of 21 checks passedROE 0/2
Low return on equity (-29.3%), below 10%.
ROA 0/1
Return on assets (-22.5%) is below the industry median (1.4%).
Profit Consistency 0/2
Not profitable for at least 3 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share history is shorter than 5 years.
Earnings Acceleration 0/1
Not enough positive earnings history to compare last year's growth with the 5-year average.
Earnings Growth vs Industry 1/1
Last year's EPS growth (69.1%) is above the industry median (1.8%).
Revenue Growth 0/2
Revenue shrank 3.0% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 2/2
Low debt to equity (5.4%), 40% or less.
Debt Trend 0/1
Debt to equity history is shorter than 5 years.
Cash Runway 0/2
Cash covers 0.8 years of the current cash burn.
PE vs Market 0/1
PE is negative or not available.
PE vs Industry 0/1
PE is negative or not available.
PBV 0/1
Price to book (2.2x) is above the industry median (0.9x).
Graham Number 0/1
Graham number needs positive earnings and book value.
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Cancer Rop Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cancer Rop Co. Ltd.
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccin…
Full company profileCancer Rop Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cancer Rop Co. Ltd. annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2014 | 2015 | 2016 | 2017 | 2018 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | 4.69B | 5.39B | 5.10B | 4.67B | 7.51B | 32.2B | 41.2B | 33.9B | 29.4B | 26.1B |
| Gross Profit | 1.90B | 2.67B | 1.96B | 672M | 1.13B | 10.1B | 7.58B | 5.14B | 3.32B | 2.84B |
| Operating Income | 373M | 561M | -682M | -3.25B | -5.09B | 2.63B | -15.4B | -21.6B | -24.3B | -22.6B |
| EBITDA | - | - | - | - | - | -44.8M | -22.5B | -49.3B | -27.5B | -22.0B |
| Net Income | 208M | 615M | -480M | -2.18B | -5.37B | -780M | -27.5B | -47.0B | -29.0B | -24.2B |
| EPS | - | - | - | - | - | -27 | -909 | -956 | -295 | -246 |
| Balance Sheet | ||||||||||
| Total Assets | 7.70B | 22.2B | 29.7B | 57.2B | 67.5B | 86.0B | 99.9B | 72.4B | 155B | 107B |
| Total Liabilities | 523M | 615M | 645M | 22.5B | 32.6B | 51.6B | 71.1B | 56.0B | 59.1B | 23.6B |
| Shareholders' Equity | 7.18B | 21.6B | 29.1B | 34.7B | 34.9B | 34.0B | 21.2B | 14.0B | 93.9B | 82.4B |
| Cash & Short-term Investments | 2.45B | 3.83B | 10.1B | 36.8B | 7.84B | 25.3B | 7.53B | 9.61B | 103B | 28.3B |
| Cash Flow | ||||||||||
| Operating Cash Flow | 784M | -841M | -1.50B | -2.14B | -4.94B | 866M | -12.1B | -20.0B | -18.9B | -30.3B |
| Capital Expenditure | 317M | 237M | 481M | 1.95B | 4.17B | 1.74B | 2.18B | 834M | 1.41B | 4.94B |
| Free Cash Flow | - | - | - | - | - | -873M | -14.2B | -20.9B | -20.3B | -35.2B |
| Ratios | ||||||||||
| ROE | 2.9% | 2.9% | -1.7% | -6.3% | -15.4% | -2.3% | -129.8% | -336.7% | -30.9% | -29.3% |
| ROA | 2.7% | 2.8% | -1.6% | -3.8% | -7.9% | -0.9% | -27.5% | -65.0% | -18.8% | -22.5% |
| Net Profit Margin | 4.4% | 11.4% | -9.4% | -46.6% | -71.4% | -2.4% | -66.6% | -138.6% | -98.9% | -92.5% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cancer Rop Co. Ltd. dividends
Cancer Rop Co. Ltd. has not paid dividends in the last 9 fiscal years.
Last stock split: 3:1 on Apr 27, 2018.
Who owns Cancer Rop Co. Ltd.
- Insiders 62.05%
- Institutions 0.00%
- Public & others 37.95%
- Shares outstanding 98.4M
- Free float 33.0M
Cancer Rop Co. Ltd. company profile
- Company name
- Cancer Rop Co. Ltd.
- Ticker
- 180400.KQ
- ISIN
- KR7180400004
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Oil, Gas & Consumable Fuels
- Employees
- 82
- Fiscal year end
- December
- Address
- Elysia Building 173, Seoul, South Korea
- Phone
- 82 2 890 8700
- Website
- dxvx.com
About Cancer Rop Co. Ltd.
Dx & Vx Co., Ltd. engages in the development and sale of bio-health care products and provides molecular genetic testing services primarily in South Korea. The company offers healthcare products, including Ofmom Carefree, oat fermented food, and biocleaners; diagnostic products, comprising CLIDEX, precision diagnostics, and in vitro diagnostic kit; health check services; CDx development services; medical data; and funeral home operation services. It provides bacterial vaccine for respiratory disease; macular degeneration drug; atopy dermatitis drugs; xeropthalmia drugs; anticancer vaccine; and new antibody drugs. Its pipeline includes Vx product, oral pediatric Covid19/influenza vaccine; new anti-cancer antibody drug; an antibody drug utilizing advanced mRNA vaccine development technique; Vx Microbiome R&D pipeline, a bacterial vaccine against respiratory diseases, new drugs targeting obesity and diagnosis etc; and Oxford Vacmedix Vaccine, an anti-cancer vaccineutilizing ROP technology. It has a research collaboration with bereum, Bioapp, CORESTEMCHEMON, Genscript PROBIO, JOINTOWN PHARMACEUTICAL GROUP,etc. The company was formerly known as Cancer Rop Co., Ltd. and changed its name to Dx & Vx Co., Ltd. in January 2022. The company was founded in 2001 and is based in Seoul, South Korea.
Cancer Rop Co. Ltd. management
5- Mr. Chi-woo AnVP & CFO
- Mr. Sungjun HanChief Technology Officer · born 1969
- Kyu-hang Lee Ph.D.Head of New Drug Development
- Mr. Won-Jin LeeHead of Invitro Diagnostics
- Mr. Geon-Sang YooVP & Head of Management BU